A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma

Exclusion Criteria

• •1. Nodular lymphocyte predominant Hodgkin lymphoma or grey zone lymphoma.
• •2. Primary site in central nervous system (CNS) or CNS involvement.
• •3. Subjects currently participating in other clinical studies or use of any investigational drug within 4 weeks prior to the first dose of CS1001.
• •4. Subjects who had systemic corticosteroid or any other immunosuppressive therapy within 14 days prior to the first dose of CS1001.
• •5. Subject who had chemotherapy, immune therapy or biological therapy as systemic anti-cancer treatment within 28 days prior to the first dose of CS1001.
• •6. Receipt of traditional medicinal herbal preparations within 7 days prior to the first dose of CS1001.
• •7. Known history of human immunodefiency virus (HIV) infection and/or acquired immune deficiency syndrome.
• •8. Subjects with active Hepatitis B or C infection.
• •9. Subjects with active tuberculosis infection.
• •10. Subjects who received prior therapy with anti-PD-1, anti-PD-L1 or anti CTLA-4 monoclonal antibody.
• •11. Female subjects who are pregnant or breast-feeding.
• •For more information regarding trial participation, please contact at cstonera@cstonepharma.com